版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领
文档简介
Accessibleversion
BofAGLOBALRESEARCH
BofASECURIES
ChinaHealthcare
AIDD101:fromsmartermodelstoclinicalvalidation
IndustryOverview
Al-drivendrugdiscoverygainsmomentum
Al-drivendrugdiscoveryanddevelopment(AIDD)ismovingfromtechnologicalpromisetowardclinicalvalidation.Weseegrowinginvestorinterest,drivenby:1)globallarge
languagemodel(LLM)leadersextendingtheircapabilitiesintodrugdiscovery;2)Al-
generatedcandidatesadvancingthroughclinicaldevelopment;and3)expanding
partnershipswithlargepharma.Webelieveaccumulatingclinicalevidencecouldsupportbroaderindustryadoptionbydemonstratingimprovementsindrugquality,developmenttime,andcost.Together,thesedevelopmentscouldaccelerateAIDDadoptionacross
pharmaceuticalR&D.ThisreportoutlinestheAIDDworkflow,competitivelandscape,andbusinessmodels,andprovidesaframeworkforassessingChina'semergingplayers.
Fasterdiscoverywithlowerexperimentalburden
Alcananalyzebiologicaldatatoprioritizetargets,generatenovelmoleculesandassesspotency,selectivity,anddevelopabilitysimultaneously.Computationalscreeningcaneliminateunsuitablecompoundsbeforesynthesis,reducingthenumberofmoleculesresearchersneedtosynthesizeandtest.Aloffersitsgreatesttimesavingsbetweentargetdiscoveryandpreclinicalcandidate(PCC)nomination,whereithelps
researchersdesign,screenandselectmoleculesfaster.Insilicoreportstarget-to-PCCtimelinesof12-18monthsvs.morethan54monthsunderitstraditionalbenchmark.BeyondPCCnomination,Alcouldmainlysupportdataanalysis,whilemandatorysafetystudies,clinicaltrials,andregulatoryreviewstilltaketimeandarehardertoshorten.
Experimentaldataandclinicalprogressgiveleadersanedge
WebelieveearlyAIDDleadersbenefitfromexperimentaldataandclinicalresultsthat
betteralgorithmsalonecannotreproduce.Theirdrylabsdesignmolecules,andtheirwetlabssynthesizeandtestthem,feedingtheresultsbackintothenextdesigncycle.Dataonwhichmoleculesworked,whichfailed,andunderwhattestingconditionscanhelpguidefuturecandidateselection.Newentrantsmusteitherobtaincomparabledataorspendtimeandresourcesgeneratingitexperimentally.Clinical-stageassetsprovideanotherheadstart,asearlymovershavealreadybeguncollectinghumansafety,dose,andefficacydata.Bettermodelsmayacceleratediscovery,butpatientrecruitment,treatment,andfollow-upstilltaketime,whichhelpsestablishedplayersretaintheirclinicallead.
Favorassetownership;BuyInsilico,IAM,andSDGR
WefavorAIDDcompaniesthatowntheirdrugcandidatesandretainrightstolicensingpaymentsandfuturedrugsales.Aclinicallydifferentiated,patent-protecteddrugcan
remainvaluableevenasnewerAlmodelsemerge.WeinitiatecoverageofInsilicoatBuy(seeourreport.InsilicoMedicineCavmanTopco:Bevondinsilico:pivotalphaseahead).supportedbyassetownership,scientist-guidedAldiscovery,andvalidationfrompharmapartnerships.WealsorateIAMBuyforitsAl-drivenmoleculardesigncapabilitiesand
earlyclinicalvalidationfromIAM1363,andSDGRBuyforitsdifferentiated
computationalplatformfordiscoveringanddevelopingadvancedcompounds.
>>Employedbyanon-USaffiliateofBofASandisnotregistered/qualifiedasaresearchanalystundertheFINRArules.
Referto"OtherImportantDisclosures"forinformationoncertainBofASecuritiesentitiesthattakeresponsibilityfortheinformationhereininparticularjurisdictions.
BofASecuritiesdoesandseekstodobusinesswithissuerscoveredinitsresearch
reports.Asaresult,investorsshouldbeawarethatthefirmmayhaveaconflictof
interestthatcouldaffecttheobjectivityofthisreport.Investorsshouldconsiderthisreportasonlyasinglefactorinmakingtheirinvestmentdecision.
Refertoimportantdisclosuresonpage24to27.AnalystCertificationonpage19.Price
ObjectiveBasis/Riskonpage17.13044271
13November2026
Equity
China
Healthcare
DavidLi>>
ResearchAnalyst
+85235084531
MerrillLynch(HongKong)
davidbo.li@
SandraSun>>ResearchAnalyst
MerrillLynch(HongKong)
sandra.sun@
AlecW.Stranahan
ResearchAnalystBofAS
alec.stranahan@
LuLi
ResearchAnalystBofAS
lu.li5@bofa.com
EthanCui>>
ResearchAnalyst
MerrillLynch(HongKong)
ethan.cui@
AIDD:Al-drivendrugdiscoveryanddevelopment
BD:businessdevelopmentIAM:lambic
LLM:Largelanguagemodel
PCC:PreclinicalcandidateSDGR:Schrodinger
Seepage17foraglossaryofadditionalterms.
BofAGLOBALRESEARCH
Aldrugdiscovery101
Alreshapingdrugdiscoveryindustry
AlisincreasinglyappliedacrosspharmaceuticalR&D,fromdiseaseunderstandingandtargetidentificationtomoleculardesign,preclinicalevaluation,andclinical-trial
optimization.Byintegratinglarge,complexdatasets,Alcanimprovehypothesisgeneration,expandthesearchablechemicalspace,andsupportmoredata-drivendevelopmentdecisions.
WebelieveAl-drivendrugdiscoveryanddevelopment(AIDD)hasthepotentialto
improvepharmaceuticalR&Dproductivitythroughthreechannels.Thefirstisfaster
discovery:Alcananalyzebiologicaldata,prioritizetargets,andoptimizemoleculesmorerapidlythantraditionalsequentialworkflows.Thesecondisalowerexperimentalburden,ascomputationalscreeningcaneliminateunsuitablemoleculesbeforesynthesis.The
thirdisbetterdevelopmentdecisions,asAlcansupportcandidateselection,translationalmodeling,patientstratification,andclinical-trialdesign.
However,AI'simpactisnotevenlydistributedacrossthedevelopmentlifecycle.The
greatestdirecttimesavingsliebetweentargetdiscoveryandpreclinicalcandidate(PCC)nomination,wherecomputationandautomationcanacceleraterepeateddesign-and-
testcycles.AfterPCCnomination,developmentisincreasinglyconstrainedbymandatorytoxicologystudies,clinicalobservationperiods,manufacturingrequirements,and
regulatoryreview.
Exhibit1:Alindrugdiscovery:workflow,contributions,andkeyAIDDplayers
Fromtargettopatients
Drug
discoverystages
1.Diseaseunderstanding
&targetdiscovery
2.Target-to-hit
3.Hit-to-lead
4.Leadoptimization
P
Precl
Cand
CC
inicalidate
5.Preclinical
development
6.Clinicaldevelopment
andbeyond
ldentifydiseasemechanisms
andvalidatetarget(s)
Findinitialactive
molecules(hits)
%
Optimizehitseriesintoleadcompounds
Improvepotency,selectivity,ADMETanddevelopability
IND-enablingstudies
(safety,PK/PD,toxicology,
manufacturing)
PhaseI-II,regulatory
approvaland
commercialization
HowAlhelps
·Integratemulti-omics,
clinicaldataandliterature
·Prioritizenoveltargets
·Explorenewindicationsforexistingtargets
(target-to-indication)
·Virtualscreeningand
generativedesign
·Predictbindingandkeyproperties
·Prioritizemolecules
forsynthesisandtesting
·Suggeststructuralmodifications
·Predictactivity,selectivity,ADMETandsyntheticfeasibility
●Balancemultiplepropertieswithiterativedesign
·Multi-parameteroptimizationwithexperimentalfeedback
·Predictsyntheticroutes
·PrioritizecandidatesforPCC(e.g,~60-200vs.~1,000
underconventionalbenchmark)
·Predictselected
safetyrisks
·PK/PDmodeling
·FormulationandCMCsupport
·Patientstratification
·Trialdesignandsiteselection
·Clinicalandreal-worlddataanalysis
●Regulatorydocumentpreparationsupport
Key
players
androles
Insilico
Medicine
Al-driven,asset-leddrugdiscoverywithproprietarypipelineand
softwarebusiness
Businessmodel/valuecapture
·Retainedpipeline(eg.,rentosertib,ISMprograms)
·Out-licensing&co-development
·Softwaresubscriptions(Pharma.Alplatform)
PandaOmicsChemistry42
(targetdiscovery&indicationproritization)(hitdiscovery,hit-to-leadandleadoptimization)
XXtalPi
Alandrobotics-enableddiscovery
solutionsforpharma/biotech,
withpartneredandproprietary
pipelines
Al-powereddiscoverysolutionsAutomatedsynthesisandtesting
(targetdiscovery,moleculedesign,propertyprediction)(A¹4Sroboticlaboratories)lterativedesign-make-test-analyze
·Partnerprograms(withpharma/biotech,e.g.SIGX1094,RTX-117,PEP08)
·Proprietarypipeline(eg,XTN004,ALX001/002/005)
·Al4Sinfrastructureandservices
(roboticlaboratoriesanddrugdiscoverysolutions)
Al-designedprotein/antibody
forsynthesisandtesting
sequences
Experimentalresults
formodelrefinement
andAl-readydata
andnext-rounddesign
GenScript
MakeResearchEasy
ExperimentalservicestosupportAl-designedproteinsandantibodies
Wet-abvalidationservices(primarilyforbiologics:proteins,antibodies,etc.)
·Contractresearchservices
·High-throughputvalidation
·Al-readydataformodeltraining
凸
Proteinexpression
andpurification
Al-readydata
(standardized,high-quality)
Genesynthesis
andconstructpreparation
D冒
Assaydevelopment→址
andfunctionaltesting
Design→Make→Test→Analyze→Learn→Redesign
Acontinuousdry-wetlabcycleacrossearlydiscovery
Source:BofAGlobalResearch
BofAGLOBALRESEARCH
2
ChinaHealthcare|13November2026
WhatisAI-baseddrugdiscovery
AIDDreferstotheuseofmachinelearning,generativemodels,foundationmodels,andautomatedworkflowsacrosspharmaceuticalresearchanddevelopment.Itshouldnotbeunderstoodasasinglealgorithmautonomouslyproducingamedicine.Drugdiscovery
involvesalargenumberofinterdependentbiological,chemical,experimental,and
operationaldecisions,andtheprocessmayencompassmorethan1,000computationaltasksandskills.
ThevalueofanAIDDplatformthereforedependsonmorethantheperformanceofanindividualmodel.Acommerciallyrelevantplatformmustidentifybiologicallymeaningfulandcommerciallyattractivetargets.Itmustgeneratemoleculeswithacceptable
potency,selectivity,andsafety,validatepredictionsexperimentally,andadvanceselectedcandidatesthroughformaldevelopment.Itmustalsodeterminewhichmodelstouse,howmuchconfidencetoplaceintheiroutputs,andwhen
additionalphysicalexperimentsarerequired.
Exhibit2:AIapplicationsacrossthedrugdiscoveryanddevelopmentworkflow
AIimprovesefficiencyfromtargetdiscoverytoclinicaldevelopmentthroughdata-drivenpredictionandoptimization.
Application
WhatAIenables
Illustrativeexample
Targetdiscovery
Enabledrugdiscoverybyidentifyingandvalidatingnewtargets.
AImodelscananalyzelargedatasetstopinpointproteinsorpathways,generatingnewtargetsforintervention.
Moleculedesign
Supportdrugdesignbygeneratingmolecularstructuresoptimizedforspecificproperties.
Generativemodelscanproposemolecules
optimizedforpotency,selectivityandbioavailability.
Clinicaltrials
ptimizeclinicaltrialsbyidentifying
patientsubgroupslikelytorespondtoaparticulartreatment.
Modelscanidentifypredictivegeneticmarkersassociatedwithtreatmentresponse.
Source:LiteratureReview,Frost&SullivanAnalysis,BofAGlobalResearch
BofAGLBALRESEARCH
HowAIisappliedacrossdrugdiscoveryanddevelopmentTargetdiscovery:findingnewdiseaseinterventionpoints
Targetdiscoveryseekstoidentifyaprotein,gene,orbiologicalpathwaythatcanbe
modulatedtotreatadisease.Conventionaltargetdiscoveryreliesonscientificliterature,individualdatasets,andexperimentalbiology.AIcanintegrateabroaderrangeof
information,incl.genomic,transcriptomic,proteomic,single-cell,disease-network,clinical,patent,andscientific-literaturedata.Indoingso,itcanpotentiallyidentifyrelationshipsthataredifficulttodetectthroughconventionalhypothesis-ledresearchalone.
Ausefultarget-discoveryplatformmustdomorethanretrieveandsummarizeexistinginformation.Itmustranktargetsbyhumandiseaseevidence,biologicalrelevance,causalsupport,druggability,potentialefficacy,safetyimplications,competitiveintensity,andbiomarkeravailability.Insilico’sPandamicsillustratesthisapproachbyintegrating
multi-omicsandotherbiologicaldatatoidentifyandprioritizepotentialtherapeutic
targets.Forrentosertib,Pandamicsanalyzedmulti-omics,single-cell,disease-networkandliteraturedatarelatedtoidiopathicpulmonaryfibrosis(IPF).Itthenprioritized
Traf2-andNck-interactingkinase(TNIK)asapotentialfibrosistargetatatimewhenTNIKwasnotyetwidelyestablishedasanIPFdrugtarget.
Moleculedesign:multi-objectiveoptimizationproblem
nceatargethasbeenselected,generativechemistrymodelscanproposenovel
chemicalstructuresandoptimizethemacrossmultipleparameters.Theobjectiveisnottogenerateasmanymoleculesaspossible.Instead,itistoidentifyalimitednumberofcandidatesthatbalancepotency,selectivity,solubility,tissueexposure,metabolic
stability,toxicity,syntheticaccessibility,patentability,formulationpotential,andmanufacturingfeasibility.
ChinaHealthcare|13November20263
4ChinaHealthcare|13November2026
Thesepropertiesareinterdependentandmayconflict.Astructuralmodificationthat
improvespotencymayreducesolubility,whileachangeintendedtoimproveexposure
mayintroducemetabolicoroff-targetliabilities.AI-enabledmoleculedesignisthereforeamulti-objectiveoptimizationprocessratherthanasimplestructure-generation
exercise.Generativemodelscanexploreabroaderchemicalspace,predictpotential
liabilities,andoptimizeseveralpropertiesinparallel,buttheresultingcompoundsmuststillbesynthesizedandvalidatedexperimentally.
Preclinicaldevelopment:identifyingfailurerisksearlier
Beforeacandidateentershumantrials,itmustundergopreclinicalevaluationto
determinewhetheritsefficacy,safety,exposureanddevelopabilityprofileisacceptable.AIcansupportthisprocessinseveralways.Theseincludepredictingabsorption,
distribution,metabolism,excretionandtoxicity(ADMET)anddrugmetabolismand
(DMPK).AIcanalsosupportoff-targetandtoxicityassessment,doseandexposuremodeling,synthetic-routeplanning,formulationanalysisandcandidateprioritization.
Identifyingweakcandidatesearliermaypreventresourcesfrombeingallocatedto
compoundsthatareunlikelytopassformalinvestigationalnewdrug(IND)-enabling
development.AIcanalsoidentifythemostinformativeexperimentsandhelpintegrateresultsacrossassays.Nevertheless,predictedpropertiesmustultimatelybeverifiedinbiochemical,cellularandanimalstudies.AIcandirectphysicalexperimentsmore
efficiently,butitdoesnoteliminatetheneedforthem.
Clinicaldevelopment:improvingdecisions,noteliminatingtimelines
AIapplicationsinclinicaldevelopmentincludebiomarkeridentification,patient
stratification,siteselection,patientmatching,protocoldesign,doseoptimization,trialmonitoringandoutcomeprediction.Modelscananalyzeelectronichealthrecords,
genomicinformationandhistoricaltrialdatatoidentifypatientpopulationsmorelikelytorespondtoatreatment.Thiscouldimproveenrollmentefficiencyandtheabilitytodetecttreatmenteffects.
urUSteam’sreportAIBasics:DrugDiscoveryalsohighlightedthedistinctionbetweenpredictingchemistryandmodelingcomplexbiology.Computationaltoolscanhelp
optimizemolecularproperties,buttranslatingtheseimprovementsintotherapeutic
benefitremainsaseparatechallenge.Better-designedmoleculesthereforestillrequireexperimentalandclinicalvalidation,andimproveddiscoveryefficiencyshouldnotbeequatedwithaprovenincreaseinclinicalsuccessrates.
AIDDcasestudy:TargetZinpain
InsilicodevelopedISM9528,apotentialfirst-in-class(FIC)small-moleculeinhibitorof
theundisclosedTargetZ,asanon-opioidanalgesicforpainmanagement.Insilico
approachedthediscoveryfromtwodirections:1)Startwiththedisease:whichbiologicaltargetsmighthelptreatpain?Pandamicsreviewedbiologicaldata,publishedresearchandotherevidencetoproduceatargetshortlist.2)Startwiththetarget:whichdiseasesmightbenefitfromadrugactingonthistarget?Pandamicscomparedthetarget
againstdatafromdifferentdiseasesandrankedthemostpromisingtreatment
opportunities.Whenthetwolistswerecompared,bothanalysespointedtoTargetZasapotentialtargetforpaintreatment.Thisgaveresearchersahypothesistotestrather
thanproofthatthetargetwouldwork.
Exhibit3:Insilico'sAl-poweredtargetidentificationforpain:TargetZ
Insilico'sAldiscoveryprocessforTargetZ
TargetZforPain
TargetIdentificationinPandaOmics
Models
OMICspanda'0mics
Diseaseof
Cross
Reference
IndicationRankinginPandaOmics
Listof
Indications
panda`Omics
Listof
Targets
Source:Insilico
BofAGLOBALRESEARCH
Next,Chemistry42helpedrefinethechemistryintoanorallyavailablecandidate.
Researchersmodeledthepossibleshapesofthetargetprotein,generatedmolecules,
andscreenedthemforintendedactivity,unwantedinteractionsandlikelybehaviorinthebody.Laboratorytestingprovidedfeedbackforfurtheroptimization,whichculminatedinISM9528.Themoleculeshowedsuperiorinvivoefficacycomparedwithmanycurrent
paintreatmentsandalsodemonstratedaverygoodsafetyprofile.
ChinaHealthcare|13November20265
BofAGLOBALRESEARCH
Exhibit4:Al-enabledcompoundgenerationandoptimization
InsilicouseChemistry42todesignthenovelmolecule
01Structureinput02Conformationmodel03Generation&selection
Generative
Chemistry
complexmodel
Compound/Scaffoldgeneration
Model
Training
Renerse-timeSDE(anrwne.drewiaa
P=民-G0G0kgPY疆+G9d'
Patentdata
extraction
AlchemistryADMET&Off-target
Filtration,clustering,scoring
04Experimentalfeedback
ExperimentalValidationSynthesis&Testing
·Bindingandfunctionalassay
·Bias/Safety/Toxic
·Developability/Liabilities
Proteinmodelconstruction
basedondiffusionmodelsand
Ontarget
binarymodel
Offtarget
binarymodel
homologyinformation
FomadSDEOnaiaive,cowiwa)
Multiple
conformation
Key
compound
Chemistry42
5ource:Insilico
BofAGLOBALRESEARCH
Al'sspeedadvantageisgreatestbeforePCCnomination
ThegreatestscopeforAl-drivenaccelerationliesbetweentargetdiscoveryandPCC
nomination.Thisperiodspansdisease-hypothesisgeneration,targetidentificationandvalidation,target-to-hitdiscovery,hit-to-leadprogression,leadoptimization,preliminaryADMETassessmentandfinalcandidateselection.Theseactivitiesinvolverepeated
cyclesofprediction,moleculedesign,synthesisandtesting,andtheycanincreasinglybeperformedcomputationallyandinparallel.
Alcanacceleratethesecyclesbyprioritizingtargets,exploringchemicalspaceand
eliminatingmoleculespredictedtobetoxic,unstableorotherwiseunsuitablebeforephysicalsynthesis.Laboratoryresourcescanthenbedirectedtowardasmallernumberofhigher-probabilitycompounds.Theearlydiscoverystageisthereforerelatively
compressiblethroughcomputation.
ThetimelinebecomesconsiderablylessflexibleafterPCCnomination.IND-enabling
toxicologystudiesrequiredefinedstudyandobservationperiods,whilechemistry,
manufacturingandcontrolsactivitiesrequirephysicalprocessdevelopmentandqualitytesting.PhaseItrialsgenerallyinvolvesequentialdoseescalationandsafetymonitoring.
PhasellandPhaseIIlstudiesdependonpatientrecruitment,treatmentduration,
endpointmeasurementandfollow-up,andregulatorysubmissionsremainsubjecttoformalreview.
6ChinaHealthcare|13November2026
BofAGLOBALRESEARCH
ChinaHealthcare|13November20267
Exhibit5:Drugdiscoveryprocessfromdiscoverytocommercial
AIDDcouldacceleratetheprocessbetweentargetdiscoverytoPCC,beyondPCCisheavilyregulatedandstandardizedtimeline.
SuperRegulated
DiseaseHypothesis
andTarget
Discovery*
PhaseⅢ
Usualytakesfrommonthstodecades.performedinacademicinstitutionsusinggovemmentfunds
Preclinical/Developmental(PCC/DC)
1-5% 1-10$0-1000
ProbabilityofSuccess%
Cycletime(years)
Costperlaunch
(capitalized).SMilions,2010data
54%
1.5
S273
75%
1.5
5166
34%
$319
70%
2.5
S314
Submission
tolaunch
Realworld
evidence
Territory
Candidate
optimization
Hitto-lead
Salesand
91%
85%
80%
S150
5414
S48
594
DiscoverySource:Insilico
Development
Salesandmarketing
BofAGLOBALRESEARCH
AI-drivensmartlaboratories
Drylab:usingcomputationalmodelsanddatatodecidewhattotest
Thedrylabisthecomputationalsideofdrugdiscovery.Itbringstogetherbiological,
chemicalandstructuraldatatogeneratehypothesesandprioritizewhatshouldbe
tested.Atthetargetstage,Alcananalyzeevidenceondiseasebiologytoidentify
potentialinterventionpoints.Atthemoleculestage,computationaltoolscanscreenorgeneratecandidatestructuresandpredictpropertiessuchastargetbinding,selectivity,ADMETandsyntheticfeasibility.Researchersusethesepredictionstoselectcompoundsforsynthesisandtodecidewhichpropertiestooptimizeinthenextdesigncycle.The
outputisthereforearankedsetofhypothesesandmoleculardesigns,notavalidateddrugcandidate.
Exhibit6:Drylabexample:avirtualcellmodel
AvirtualcellisacomputationalmodelofalivingcellThemodelpredictshowthecellresponds.
COMPOUNDPERTURBATION
Ilustrativesyntheticoutputfordesonstzaticn-notrealmodelpzedictions.It
mirrorstheclassofconditionalmut1-omtcsgenezationdescribedinthe
Source:Insilico
BofAGLOBALRESEARCH
Wetlab:runningphysicalexperimentstodeterminewhatactuallyhappens
Thewetlabconductsresearchthroughphysicalexperiments.Itsworkmayinclude
producingtargetproteins,synthesizingcompounds,measuringbindingandbiological
activity,assessingeffectsincells,andevaluatingandsafetyin
preclinicalmodels.Theseexperimentsestablishwhetheraproposedmoleculecanbe
madeandwhetheritsobservedpropertiessupportfurtheroptimization.Somestepscanbeautomated,butwet-labworkisnotsynonymouswithanautomatedlaboratory,sinceexperimentsmayalsobeperformedmanuallyorbyexternalresearchpartners.The
outputisexperimentalevidence,whichmayconfirmorchallengedry-labpredictions.
Closingtheloopbetweenpredictionandexperimentation
Generativemodelscandesignmoleculesrapidly,butthevalueofthosedesignsdependsonhowquicklytheycanbesynthesizedandtested.Withoutefficientlaboratory
validation,greatercomputationalspeedcouldsimplyshiftthebottleneckfrommoleculedesigntophysicalexperimentation.
AI-drivensmartlaboratoriesaddressthisbottleneckbyintegratingmoleculardesign,
compoundsynthesis,samplemanagement,cellculture,biologicalscreening,high-contentimaging,multi-omicsanalysisandexperimental-datainterpretation.Theiroperating
modelcanbesummarizedas:predict,design,synthesize,test,analyzeandredesign.AIfirstnarrowstherangeoftargetsormoleculesthatrequirephysicalinvestigation.Automatedequipmentthensynthesizesandteststheselectedcandidates,andthe
resultingdataarefedbackintothecomputationalplatformtoinformthenextdesigncycle.Theobjectiveisnottoeliminateexperimentsbuttoconductthemmore
selectively,consistentlyandrapidly.
Proprietaryexperimentaldatareinforcetheplatform
Closed-loopexperimentationgeneratesproprietarydataacrosstargetbiology,structure-activityrelationships,potency,selectivity,ADMET,animal,toxicity,
biomarkers,andclinicaloutcomes.Ifthesedataareconsistentlystructuredandfedbackintotheplatform,eachprogramcanpotentiallyimprovefuturemodelselectionand
candidatedesign.
Thiscreatesareinforcingflywheel.Moreprogramsgeneratemoreproprietary
experimentaldata,whichsupportbetterpredictionsanddecisionsandhigher-qualitycandidates.Thesecandidatesinturnbringadditionalclinicalandpartnershipvalidationandfurtherdatageneration.However,datavolumealonedoesnotcreateamoat.Thedatamustbehighquality,relevantacrossprogramsanddemonstratedtoimprove
prospectiveperformance.
Exhibit7:AI-drivensmartlaboratoriesdrugdiscoveryInnovationscanbecategorizedintofourkeyfunctionalareas
Keyarea
AIcapabilitiesandimpact
Automation
Automatedsystemsenhanceexperimentalprecisionandreliabilitybymaintainingcontrolledreactionconditionsandenablingcontinuousmonitoringoflaboratory
environments.TheresultingdatagenerationsupportsongoingoptimizationofR&Dprocessesandimprovesoverallefficiency.
Moleculedesignandsynthesis
AI-drivengenerativemodelsdesignnoveldrug-likemolecules,whicharesynthesized
throughautomatedplatformscapableofprocessinglargechemicallibraries.Thisiterativeprocessenablescontinuousrefinementofmolecularcandidatesbasedonexperimentaloutcomes.
Biologicaltestingand
Followingsynthesis,compoundsundergohigh-throughputbiologicalscreening,
supportedbyautomatedworkflowsthatgenerateandanalyzemulti-omicdata.Theseinsightsarefedbackintothediscoveryprocesstoimprovecandidateselectionand
温馨提示
- 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- (2026年)烧烤店食品安全管理制度规范
- 四年级英语教学设计 Lets learn Part A 预习
- 初中数学七年级上册《有理数的乘方与混合运算》教学设计
- 初中美术八年级《中国古建筑》教案
- 小学三年级劳动《小帆船》项目式教学设计:从材料认知到航行测试的核心素养落实
- 八年级生物《人体内的气体交换》教学设计
- 小学五年级英语Unit 6 Nature and us Part B Read and write教学设计
- 小学六年级生命安全教育主题班会教案-安全在我心
- 初中八年级地理教学设计:专题三 综合思维 河流特征与开发利用
- 小学三年级科学《空气的性质》单元整体教学设计
- 江苏无锡市2026-2027学年高三上学期期中考试语文试题
- 高压配电柜安全操作规程
- 老年人抗菌药物的使用与注意事项
- 2026年护士条例学习解读课件(含案例分析)
- 2026年湖南普通高中学业水平选择性考试化学真题及答案
- 露天矿山开采施工方案
- 钠离子电池用硬炭负极材料技术要求
- 2026版中央安全生产考核巡查明查暗访应知应会
- 驾驶服务外包投标方案
- 2026年兰州市红古区事业单位招聘笔试参考题库及答案解析
- 钢结构冬季施工方案
评论
0/150
提交评论